Pathways and dead ends in the diagnostics of primary aldosteronism
We present a patient with a tumour of the left adrenal gland who has been treated for resistant hypertension and hypokalaemia for years. Primary aldosteronism was confirmed but despite multiple attempts of adrenal vein sampling we were unable to prove unilateral disease. Treatment with mineralocorticoid receptor antagonists was not successful, however no clear indication for operative treatment was present. Patient's clinical and laboratory characteristics pointed to unilateral disease, so he was referred for PET CT with 11-C-metomidate in the United Kingdom. Unilateral disease was confirmed, and the patient was cured with left-sided laparoscopic adrenalectomy.
Accetto R, Salobir B, Brguljan Hitij J, Dolenc P. Slovenske smernice za obravnavo hipertenzije 2013. Zdrav Vestn. 2014;83:727–58.
Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003 Nov;139(9):761–76. https://doi.org/10.7326/0003-4819-139-9-200311040-00011 PMID:14597461
Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44(1):1–85. https://doi.org/10.1080/10408360600931831 PMID:17175520
Kocjan T. Rational Approach to a Patient with Suspected Primary Aldosteronism. In: Lew JI, ed. Clinical Management of Adrenal Tumors [Internet]. InTech; 2017 [cited 2018 Apr 4]. Available from: http://www.intechopen.com/books/clinical-management-of-adrenal-tumors/rational-approach-to-a-patient-with-suspected-primary-aldosteronism https://doi.org/10.5772/66965.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061 PMID:26934393
Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007 May;66(5):607–18. https://doi.org/10.1111/j.1365-2265.2007.02775.x PMID:17492946
Funder JW. Primary aldosteronism and salt. Pflugers Arch. 2015 Mar;467(3):587–94. https://doi.org/10.1007/s00424-014-1658-0 PMID:25502114
Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017 Apr;69(14):1811–20. https://doi.org/10.1016/j.jacc.2017.01.052 PMID:28385310
Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies—a review of the current literature. Horm Metab Res. 2012 Mar;44(3):157–62. https://doi.org/10.1055/s-0031-1295438 PMID:22135219
Monticone S, Viola A, Rossato D, Veglio F, Reincke M, Gomez-Sanchez C, et al. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 2015 Apr;3(4):296–303. https://doi.org/10.1016/S2213-8587(14)70069-5 PMID:24831990
Steichen O, Zinzindohoué F, Plouin PF, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res. 2012 Mar;44(3):221–7. https://doi.org/10.1055/s-0031-1299681 PMID:22395801
Williams TA, Lenders JW, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689–99. https://doi.org/10.1016/S2213-8587(17)30135-3 PMID:28576687
Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006 Jul;91(7):2618–23. https://doi.org/10.1210/jc.2006-0078 PMID:16670162
Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009 Sep;151(5):329–37. https://doi.org/10.7326/0003-4819-151-5-200909010-00007 PMID:19721021
Moors M, Williams TA, Deinum J, Eisenhofer G, Reincke M, Lenders JW. Steroid Hormone Production in Patients with Aldosterone Producing Adenomas. Horm Metab Res. 2015 Dec;47(13):967–72. https://doi.org/10.1055/s-0035-1565225 PMID:26667800
Ceolotto G, Antonelli G, Maiolino G, Cesari M, Rossitto G, Bisogni V, et al. Androstenedione and 17-α-Hydroxyprogesterone Are Better Indicators of Adrenal Vein Sampling Selectivity Than Cortisol. Hypertension. 2017 Aug;70(2):342–6. https://doi.org/10.1161/HYPERTENSIONAHA.117.09415 PMID:28584010
Dekkers T, Deinum J, Schultzekool LJ, Blondin D, Vonend O, Hermus AR, et al. Plasma metanephrine for assessing the selectivity of adrenal venous sampling. Hypertension. 2013 Dec;62(6):1152–7. https://doi.org/10.1161/HYPERTENSIONAHA.113.01601 PMID:24082051
Strajina V, Al-Hilli Z, Andrews JC, Bancos I, Thompson GB, Farley DR, et al. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal aldosterone production can be used in clinical decision making. Surgery. 2018 Apr;163(4):801–6. https://doi.org/10.1016/j.surg.2017.10.012 PMID:29174432
Dekkers T, Prejbisz A, Kool LJ, Groenewoud HJ, Velema M, Spiering W, et al.; SPARTACUS Investigators. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016 Sep;4(9):739–46. https://doi.org/10.1016/S2213-8587(16)30100-0 PMID:27325147
Rossi GP, Funder JW. Adrenal Venous Sampling Versus Computed Tomographic Scan to Determine Treatment in Primary Aldosteronism (The SPARTACUS Trial): A Critique. Hypertension. 2017 Mar;69(3):396–7. https://doi.org/10.1161/HYPERTENSIONAHA.116.08820 PMID:28137983
Bardet S, Chamontin B, Douillard C, Pagny JY, Hernigou A, Joffre F, et al. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: subtype diagnosis. Ann Endocrinol (Paris). 2016 Jul;77(3):208–13. https://doi.org/10.1016/j.ando.2016.01.008 PMID:27036860
Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015 Jun;22(3):150–6. https://doi.org/10.1097/MED.0000000000000148 PMID:25871964
Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012 Jan;97(1):100–9. https://doi.org/10.1210/jc.2011-1537 PMID:22112805
Ouyang J, Hardy R, Brown M, Helliwell T, Gurnell M, Cuthbertson DJ. 11C-metomidate PET-CT scanning can identify aldosterone-producing adenomas after unsuccessful lateralisation with CT/MRI and adrenal venous sampling. J Hum Hypertens. 2017 Jul;31(7):483–4. https://doi.org/10.1038/jhh.2017.9 PMID:28276424
Copyright (c) 2019 Slovenian Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.